Options de traitement systémique, Centre de Preuves en Dermatologie

Guidelines atopic dermatitis Updated on Jul 25

Responsibility

The information provided by this website comes from sources deemed reliable. However, the Société Française de Dermatologie recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The Société Française de Dermatologie cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

I have read and accept the general conditions of use of this website

Back to decision-making tree Print last updated on 09/02/2026

Biotherapies

Lebrikizumab: in adult patients and adolescents from 12 years of age

Lebrikizumab is an IgG4 monoclonal antibody that specifically binds to IL-13 and prevents the formation of the IL-13Rα1/IL-4Rα complex.

In France, it has Marketing Authorization (MA) and reimbursement for the treatment of moderate-to-severe AD in adults and adolescents from 12 years of age.

Recommended dose:

250 mg every 2 weeks after a loading dose of 500 mg at treatment initiation. Once clinical response is achieved, the recommended maintenance dose of lebrikizumab is 250 mg every four weeks.

Reported AEs are mostly mild to moderate, not requiring treatment discontinuation, including HSV infections and conjunctivitis.

Concomitant use of emollients, TCS, TCIs, and phototherapy is possible.

➜ Tralokinumab

Back to decision-making tree Print

Was this article helpful to you?
Your opinion counts!

This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.